Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL493704 | 0.98 | CHRM1 (0.47) | CHRM1KMT2AMEN1APEX1TDP1 | |
| SCHEMBL29585090 | 0.87 | KMT2A (0.47) | CHRM1KMT2AMEN1APEX1TDP1 | |
| SCHEMBL12482578 | 0.83 | CHRM1 (0.59) | CHRM1KMT2AMEN1APEX1TDP1 | |
| SCHEMBL9425800 | 0.82 | CHRM1 (0.51) | CHRM1KMT2AMEN1APEX1TDP1 | |
| Hydrochloric Acid SCHEMBL1999076 | 0.81 | CHRM1 (0.57) | CHRM1KMT2AMEN1APEX1TDP1 | |
| Hydrochloric Acid SCHEMBL29722948 | 0.81 | CHRM1 (0.50) | CHRM1KMT2AMEN1APEX1TDP1 | |
| SCHEMBL22359043 | 0.80 | CHRNB2 (0.35) | CHRM1KMT2AMEN1APEX1TDP1 | |
| SCHEMBL1437816 | 0.79 | CHRM1 (0.56) | CHRM1KMT2AMEN1APEX1TDP1 | |
| SCHEMBL6108276 | 0.78 | CHRM1 (0.54) | CHRM1KMT2AMEN1APEX1TDP1 | |
| Hydrochloric Acid SCHEMBL27907016 | 0.76 | CHRM1 (0.53) | CHRM1KMT2AMEN1APEX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | claimed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | claimed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | claimed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270398-A1 | New Compounds III | CYP11B2, CYP11B1, SDHA | CHRM1 2610/4885KMT2A 4510/4885MEN1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.